GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocure Technology Inc (XCNQ:CURE) » Definitions » Cyclically Adjusted PB Ratio

Biocure Technology (XCNQ:CURE) Cyclically Adjusted PB Ratio : 0.28 (As of Jan. 19, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Biocure Technology Cyclically Adjusted PB Ratio?

As of today (2025-01-19), Biocure Technology's current share price is C$0.045. Biocure Technology's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 was C$0.16. Biocure Technology's Cyclically Adjusted PB Ratio for today is 0.28.

The historical rank and industry rank for Biocure Technology's Cyclically Adjusted PB Ratio or its related term are showing as below:

XCNQ:CURE' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.1   Med: 3.56   Max: 30.75
Current: 0.28

During the past years, Biocure Technology's highest Cyclically Adjusted PB Ratio was 30.75. The lowest was 0.10. And the median was 3.56.

XCNQ:CURE's Cyclically Adjusted PB Ratio is ranked better than
78.49% of 595 companies
in the Biotechnology industry
Industry Median: 1.57 vs XCNQ:CURE: 0.28

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biocure Technology's adjusted book value per share data for the three months ended in Sep. 2024 was C$0.148. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$0.16 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Biocure Technology Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Biocure Technology's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocure Technology Cyclically Adjusted PB Ratio Chart

Biocure Technology Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.76 7.28 4.22 0.40 0.71

Biocure Technology Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.71 0.75 0.78 0.56

Competitive Comparison of Biocure Technology's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Biocure Technology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocure Technology's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocure Technology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biocure Technology's Cyclically Adjusted PB Ratio falls into.



Biocure Technology Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biocure Technology's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.045/0.16
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocure Technology's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Biocure Technology's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.148/127.2847*127.2847
=0.148

Current CPI (Sep. 2024) = 127.2847.

Biocure Technology Quarterly Data

Book Value per Share CPI Adj_Book
201412 0.429 98.367 0.555
201503 0.425 99.789 0.542
201506 0.421 100.500 0.533
201509 0.417 100.421 0.529
201512 0.409 99.947 0.521
201603 0.408 101.054 0.514
201606 0.405 102.002 0.505
201609 0.396 101.765 0.495
201612 -0.058 101.449 -0.073
201703 0.390 102.634 0.484
201706 0.385 103.029 0.476
201709 0.380 103.345 0.468
201712 0.278 103.345 0.342
201803 0.220 105.004 0.267
201806 0.208 105.557 0.251
201809 0.204 105.636 0.246
201812 0.084 105.399 0.101
201903 0.138 106.979 0.164
201906 0.093 107.690 0.110
201909 0.099 107.611 0.117
201912 -0.027 107.769 -0.032
202003 -0.009 107.927 -0.011
202006 -0.020 108.401 -0.023
202009 -0.068 108.164 -0.080
202012 -0.181 108.559 -0.212
202103 -0.198 110.298 -0.228
202106 -0.297 111.720 -0.338
202109 -0.251 112.905 -0.283
202112 -0.045 113.774 -0.050
202203 -0.064 117.646 -0.069
202206 -0.079 120.806 -0.083
202209 -0.096 120.648 -0.101
202212 -0.163 120.964 -0.172
202303 -0.185 122.702 -0.192
202306 0.298 124.203 0.305
202309 0.285 125.230 0.290
202312 0.153 125.072 0.156
202403 0.151 126.258 0.152
202406 0.149 127.522 0.149
202409 0.148 127.285 0.148

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biocure Technology  (XCNQ:CURE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biocure Technology Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Biocure Technology's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocure Technology Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 2E9
Biocure Technology Inc is a South Korean-based Bio-Pharmaceutical company specializing in the development and potential commercialization of biosimilar pharmaceutical products. It Developing Biosimilars and CAR-T Cell pharmaceuticals. Its products are CAR-T Cell Therapy, Interferon Beta, Ranibizumab, and PEG-Filgrastim.
Executives
Konstantin Lichtenwald Director, Senior Officer

Biocure Technology Headlines